Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Recommended Global Oncology & Cancer Webinars & Conferences

Asia Pacific & Middle East

Global Cancer 2022

About Conference

About Conference:

6th Global Summit on Cancer with the theme "LIVING WITH CANCER IN THE 21ST CENTURY" is scheduled on June 15-16, 2022 at Brisbane, Australia.

6th Global Summit on Cancer will offer an unmatched vision to get allied with leading Scientists, Academicians, and Specialists & Medical professionals coming from all over the world. It is also an enormous platform to present and deliberate the most significant advances and concerns in the field of Cancer Science, Hematology and Oncology.

This two-day Conference will give the chance to endorse knowledge interchange and network with a wide audience in the arena of Cancer to share the newest research that will allow the best outcomes. Incredibly famous speakers, the latest progressions, improvements, and the most up to data in Oncology are marks of Conference.

6th Global Summit on Cancer offer a front line program of admired worldwide speakers, pro simultaneous sessions, short paper and notice summaries drawing in more than 200 specialists from Cancer Researchers, Professors, Oncology Researchers, Oncology Faculty, Medical Colleges, Scientists, Doctors, Professors, Oncology Lecturers, Researchers, Pharmaceutical Industries, Healthcare Industries, Directors of Association and Societies, Cancer and Radiology Training Institutes, Staff development educators.

Target Audience:

Radiology and Oncology Students, Cancer Researchers, Scientists, Radiology and Oncology Researchers, Radiology and Oncology Faculty, Medical Colleges, Scientists, Doctors, Professors, Oncology Lecturers, Researchers, Pharmaceutical Industries, Healthcare Industries, Directors of Association and Societies, Cancer and Radiology Training Institutes, Staff development educators.




Track 01: Biology of Cancer:

Cancer terms an enormous spectrum of diseases that all instigate from uncontrolled cellular growth. Broadly allocated into benign tumors (unable to metastasize) or malignant tumors (able to invade normal tissues), cancers are further defined and classified by their cell type, tissue, or organ of origin. Cancer remains the number two cause of death in the U.S., second only to heart disease, and the Intramural Research Program (IRP) is dedicated to proceeding research, building expertise, and leveraging resources to address this global challenge. Our scientists are continually learning more about the sources of cancer, and emerging new and better ways to prevent, detect, and treat it.

Normal cells make up tissues, and when these cells lose their capability to behave as a specified, controlled and coordinated unit (dedifferentiation) the defect leads to disarray amongst the cell population. When this occurs, a tumor is formed. Cancer is a term recitation a large variety of disorders of proliferation. The specific disorder may differ from tissue type to tissue type. A single tumor may even have dissimilar populations of cells within it with differing procedures that have gone awry.

Track 02: Cause of Cancer:

Cancer is instigated by changes (mutations) to the DNA within cells. The DNA inside a cell is wrapped into a large number of individual genes, each of which comprises a set of instructions telling the cell what functions to perform, as well as how to grow and divide. The aspects elaborate may be genetic, environmental, or constitutional characteristics of the individual.

Diagnosis, treatment, and prognosis for childhood cancers are dissimilar than for adult cancers. The main variances are the survival rate and the cause of the cancer. The overall five-year endurance rate for childhood cancer is about 80%, while in adult cancers the survival rate is 68%. This difference is thought to be because childhood cancer is more alert to therapy and a child can tolerate more aggressive therapy.

Track 03:  Cancer Imaging Techniques:

An imaging assessment is a way to let doctors see what’s going on inside your body. These investigations send forms of energy (like x-rays, sound waves, radioactive particles, or magnetic fields) through your body. Your body tissues change the energy outlines to make an image or picture. These pictures show how your insides look and work so that health care providers can see variations that may be caused by diseases like cancer. Imaging tests are only fragment of cancer diagnosis and treatment. A comprehensive cancer work-up also contains talking about your medical history (asking questions about your symptoms and risk factors), a physical exam, and blood work or other lab tests. Many health care providers design x-rays or other imaging tests before treatment starts. These representations are then used to track changes during treatment. These are called baseline studies since they show how things detected at the start. They can be associated with later images to see the consequences of treatment over time.

Track 04: Clinical Research & Clinical Trials of cancer:

Clinical trials for cancer are research studies that associate the most effective known treatment for a precise type or stage of cancer with a new approach. This can be a new drug, or mixture of drugs or a dissimilar way of using established therapies. There are trials that comprise new approaches to surgery and radiation therapy. There are clinical trials for all type of cancer. While many trials emphasis on late stage disease, there are also trials to prevent cancer, improve early diagnosis, stop the cancer from coming back, reduce side effects or improve quality of life.

The persistence of clinical trials is to find ways to more efficiently prevent, diagnose, or treat disease. Every drug and process that is used in cancer treatment was once studied as a part of a clinical trial.

Track 05: Treatments of Cancer:

Cancer treatment is the use of surgery, radiation, medications and other therapies to cure a cancer shrink a cancer or stop the development of a cancer. Many cancer treatments exist. Depending on your certain condition, you may receive one treatment or you may receive a combination of treatments. The aim of cancer treatment is to accomplish a cure for your cancer, allowing you to live a normal life span. This may or may not be probable, depending on your specific situation. If a cure isn't possible, your treatments may be used to shrink your cancer or deliberate the development of your cancer to allow you to live symptom free for as long as possible.

Track 06: Cancer Epidemiology:

The epidemiology of cancer is the study of the features affecting cancer, as a way to assume possible trends and causes. The study of cancer epidemiology uses epidemiological methods to discover the source of cancer and to recognize and progress improved treatments.

This extent of study must resist with problems of lead time bias and length time bias. Lead time bias is the notion that early diagnosis may artificially inflate the survival statistics of a cancer, without really improving the usual history of the disease. Length bias is the concept that slower growing, more indolent tumors are more likely to be analyzed by screening tests, but improvements in diagnosing more cases of indolent cancer may not interpret into better patient outcomes after the implementation of screening programs.

Track 07: Cancer Pathophysiology:

Cancer has a complex Pathophysiology. Pathologists are physicians who are anxious primarily with the study of infection in all its aspects. This comprises cause of the disease, diagnosis, how the disease grows (pathogenesis), mechanism and natural course of the disease. They also deal with biochemical features, progression, and prognosis or consequence of the disease. Pathology of cancers and further complex disorders have undergone a alteration after expansion of technologies like immunohistochemistry, flow cytometry, and molecular biologic approaches to cancer diagnosis.

Track 08: Cancer Prognosis

Prognosis of cancers frequently means the assessment of success with treatment and probabilities of recovery. The kind of cancer and where it is in your body. The stage of the cancer, which states to the size of the cancer and if it has spread to other parts of your body. The cancer's grade, which states to how irregular the cancer cells look under a microscope. Many factors can impact the prognosis of a person with cancer. Among the most important are the type and site of the cancer, the stage of the disease (the extent to which the cancer has spread in the body), and the cancer’s grade (how abnormal the cancer cells look under a microscope—an indicator of how quickly the cancer is likely to grow and spread).

Track 09: Cancer Vaccines:

A cancer vaccine is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat current cancer are known as therapeutic cancer vaccines. Many of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

Some researcher’s privilege that cancerous cells routinely arise and are demolished by the immune system (immunosurveillance); and that tumors form when the immune system fails to abolish them. Some types of cancer, such as cervical cancer and liver cancer, are triggered by viruses (oncoviruses). Traditional vaccines against those viruses, such as the HPV vaccine and the hepatitis B vaccine, avoid those types of cancer. Other cancers are to some point caused by bacterial infections (e.g. stomach cancer and Helicobacter pylori). Traditional vaccines against cancer-causing bacteria (oncobacteria) are not further discussed in this article.

Track 10: Cancer Nanotechnology:

Nanotechnology has the potential to completely change how we analyze and treat cancer. Although scientists and engineers have only recently (ca. 1980's) developed the capability to industrialize technologies at this scale, there has been good development in translating Nano-based cancer therapies and diagnostics into the clinic and numerous more are in development.

Nanotechnology is the claim of materials, functionalized structures, devices, or systems at the atomic, molecular, or macromolecular scales. At these length scales, about the 1-100 nanometer range as defined by the U.S. National Nanotechnology Initiative (NNI) , exclusive and specific physical properties of matter exist, which can be eagerly manipulated for a desired application or effect. Furthermore, Nano scale structure can be used as individual entities or unified into larger material components, systems, and architectures.

Track 11: MicroRNA and Cancer:

MiRNAs might function as either oncogenes or tumor suppressors under assured conditions. The dysregulated MiRNAs have been shown to mark the hallmarks of cancer, including supporting proliferative signaling, evading growth suppressors, resisting cell death, activating invasion and metastasis, and inducing angiogenesis. MiRNA expression is tightly controlled by different transcription factors, so abnormal expression of MiRNA in cancer could be due to dysregulation of some key transcription factors, such as c-Myc and p53.

Track 12: Breast cancer and cervical cancer:

Breast cancer can arise in women and rarely in men. Breast cancer cells typically form a tumor that can often be seen on an x-ray or felt as a lump. Breast cancer occurs nearly entirely in women, but men can get breast cancer, too. It’s significant to understand that most breast lumps are benign and not cancer (malignant). Non-cancerous breast tumors are abnormal growths, but they do not extent outside of the breast. They are not life threatening, but some types of benign breast lumps can surge a woman's risk of getting breast cancer. Any breast lump or change needs to be patterned by a health care professional to regulate if it is benign or malignant (cancer) and if it might affect your future cancer risk.

Cervical cancer is a type of cancer that happens in the cells of the cervix — the lower part of the uterus that connects to the vagina. Various strains of the human papillomavirus (HPV), a sexually transmitted infection, play a part in causing most cervical cancer. When exposed to HPV, the body's immune system typically averts the virus from doing harm. In a small percentage of people, however, the virus endures for years, contributing to the process that grounds some cervical cells to become cancer cells.

Track 13: Cancer Screening & Diagnosis:

Cancer screening tests are tests that look for the existence of cancer in healthy people or people without signs of cancer. Cancer screening tests are intended to find cancers at an early stage when they are more treatable Cancer screening helps find cancer initial before you have symptoms when it is easier to treat. Cancer screening helps find cancer before it spreads when it is easier to treat. Early finding may mean less treatment and less time spent recovering. The earlier a cancer is noticed, the better your chance of survival. There are some cancers which can really be screened and identified by simple tests and they are cancers of the breast, cervix, colon, prostate, lung, skin and oral cancers.

Depending on where the cancer is located, a physical exam may give some idea as to how much cancer there is. Imaging tests like x-rays, CT scans, MRIs, ultrasound, and PET scans may also give information about how much and where cancer is in the body. Effective diagnostic testing is used to confirm or eliminate the presence of disease, monitor the disease process, and to plan for and evaluate the effectiveness of treatment. In some cases, it is necessary to repeat testing when a person's condition has changed, if a sample collected was not of good quality, or an abnormal test result needs to be confirmed.


Market Analysis

Market Overview:

The global cancer therapy market was valued at approximately USD 158 billion in 2020, and it is expected to witness revenue of USD 268 billion in 2026, with a CAGR of 9.15% over the forecast period.

The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. Also, the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, to be postponed unless the risks outweighed the benefits and to secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the cancer therapy market. However, the situation is expected to gradually improve.

The global cancer therapy market is estimated to register a CAGR of 9.15% during the forecast period. The factors that are driving the market growth include increasing patient assistance programs (PAPs), increasing government initiatives for cancer awareness, rising prevalence of cancer worldwide, and strong R&D initiatives from key players, along with the increasing demand for personalized medicine.

Key Market Trends:

The Targeted Therapy Segment is probable to Show the Fastest Growth in the Forecast Period. Targeted therapy is an action used for cancer, in which the drugs work by directing the specific genes or proteins that are present in the cancer cells. There are numerous types of targeted therapies for cancers, such as hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, signal transduction inhibitors, and many other therapies.

In the COVID-19 era, nearly 88% of the cancer care centers faced challenges in delivering usual cancer care for many reasons, including precautionary measures, lack of personal protective equipment, and staff shortage as per the research article published in the JCO Global Oncology 2020. Furthermore, this impact was more pronounced in low-income countries. Therefore, COVID-19 is probable to hinder the number of cancer therapies offered to cancer patients, which is anticipated to impact the studied segment.

Targeted therapy is a quickly growing field of cancer research, and researchers are reviewing many new targets. For example, the human epidermal growth factor receptor 2 protein (HER-2) is articulated at high levels on the surface of some cancer cells. Several targeted therapies are directed against HER-2, including trastuzumab (Herceptin), which is permitted to treat certain breast and stomach cancers that overexpress HER-2. In April 2020, the US FDA approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer. Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate, which targets the Trop-2 receptor that helps cancer grow, divide, and spread. Moreover, in May 2020, the US FDA approved Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung cancer (NSCLC), and it is the first FDA-approved targeted therapy to treat NSCLC with specific mutations. Thus, in opinion of the increasing product approvals and high research activities related to targeted therapies against cancers, the studied segment is expected to grow over the forecast period.

Competitive Landscape:

The cancer therapy market is extremely competitive and consists of several major players. In terms of market share, a few of the major players currently lead the market. The players, namely, Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, and Johnson and Johnson, hold significant shares in the cancer therapy market. The strategic alliances and the increasing investment in research on oncology by the key players aid in securing their position and presence worldwide. For instance, in January 2019, GlaxoSmithKline PLC acquired TESARO Inc., an oncology-based biopharmaceutical company, leading to the expansion of GSK's pipeline and commercial capability in oncology.

The global cancer therapeutics market size was esteemed at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026. Cancer therapeutics comprises the use and administration of chemotherapy and oncology drugs to treat cancer.

Increase in cancer prevalence, surge in collaboration between pharmaceutical companies, and growth in cancer research are the key issues that augment the development of the cancer therapeutics market. Furthermore, growth in geriatric population is expected to boost the market growth.

Furthermore, the global cancer therapeutics market prediction is also examined through the region vertical. By region, North America is anticipated to lodge the largest share by 2026, owing to heavy funding by various organizations and upsurge in adoption of cancer therapeutics in this region. Moreover, rise in R&D investments is anticipated to ease the market growth during the forecast period


To Collaborate Scientific Professionals around the World

Conference Date June 15-16, 2022

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by